Role of p38 MAP Kinase Signal Transduction in Solid Tumors

Genes and Cancer

Volumn 4, Issue 9-10, 2013, Pages 342-359

  Koul, Hari K ^a,b   Pal, Mantu ^a,b   Koul, Sweaty ^a,c  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Louisiana State University School of Medicine Shreveport   (United States)

Author keywords

mitogen activated protein kinase (MAPK); p38 signaling pathway; solid tumors

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE KINASE 6; MITOGEN ACTIVATED PROTEIN KINASE P38; STAT1 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR NRF2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; CANCER PATIENT; CANCER SURVIVAL; CELL DEATH; CELL DIFFERENTIATION; CELL INVASION; CELL MIGRATION; DISEASE ASSOCIATION; DOWN REGULATION; GENE EXPRESSION; HUMAN; LIVER CANCER; LUNG CANCER; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; UPREGULATION;

EID: 84890447356     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601913507951     Document Type: Review

References (274)

1. Kim TW,Michniewicz M,Bergmann DC,Wang ZY.Brassinosteroid regulates stomatal development by GSK3-mediated inhibition of a MAPK pathway.Nature. 2012;482 (7385): 419-22.
2. Sayama K,Hanakawa Y,Nagai H, et al.Transforming growth factor-beta-activated kinase 1 is essential for differentiation and the prevention of apoptosis in epidermis.J Biol Chem. 2006;281 (31): 22013-20.
3. Fang WB,Jokar I,Zou A,Lambert D,Dendukuri P,Cheng N.CCL2/CCR2 chemokine signaling coordinates survival and motility of breast cancer cells through Smad3 protein- and p42/44 mitogen-activated protein kinase (MAPK)-dependent mechanisms.J Biol Chem. 2012;287 (43): 36593-608.
4. Sayama K,Yamasaki K,Hanakawa Y,Shirakata Y,Tokumaru S,Ijuin T,Takenawa T,Hashimoto K.Phosphatidylinositol 3-kinase is a key regulator of early phase differentiation in keratinocytes.J Biol Chem. 2002;277 (43): 40390-6.
5. Lawson SK,Dobrikova EY,Shveygert M,Gromeier M.p38alpha mitogen-activated protein kinase depletion and repression of signal transduction to translation machinery by miR-124 and -128 in neurons.Mol Cell Biol. 2013;33 (1): 127-35.
6. Yu Y,Richardson DR.Cellular iron depletion stimulates the JNK and p38 MAPK signaling transduction pathways, dissociation of ASK1-thioredoxin, and activation of ASK1.J Biol Chem. 2011;286 (17): 15413-27.
7. Werlen G,Hausmann B,Naeher D,Palmer E.Signaling life and death in the thymus: timing is everything.Science. 2003;299 (5614): 1859-63.
8. Posas F,Saito H.Osmotic activation of the HOG MAPK pathway via Ste11p MAPKKK: scaffold role of Pbs2p MAPKK.Science. 1997;276 (5319): 1702-5.
9. Vassalli G,Milano G,Moccetti T.Role of mitogen-activated protein kinases in myocardial ischemia-reperfusion injury during heart transplantation.J Transplant. 2012;2012:928954.
10. Raingeaud J,Gupta S,Rogers JS, et al.Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine.J Biol Chem. 1995;270 (13): 7420-6.
11. Vander Griend DJ,Kocherginsky M,Hickson JA,Stadler WM,Lin A,Rinker-Schaeffer CW.Suppression of metastatic colonization by the context-dependent activation of the c-Jun NH2-terminal kinase kinases JNKK1/MKK4 and MKK7.Cancer Res. 2005;65 (23): 10984-91.
12. Cuadrado A,Nebreda AR.Mechanisms and functions of p38 MAPK signalling.Biochem J. 2010;429 (3): 403-17.
13. New L,Han J.The p38 MAP kinase pathway and its biological function.Trends Cardiovasc Med. 1998;8 (5): 220-8.
14. Frazier WJ,Xue J,Luce WA,Liu Y.MAPK signaling drives inflammation in LPS-stimulated cardiomyocytes: the route of crosstalk to G-protein-coupled receptors.PLoS One. 2012;7 (11): e50071.
15. Hsu YC,Ip MM.Conjugated linoleic acid-induced apoptosis in mouse mammary tumor cells is mediated by both G protein coupled receptor-dependent activation of the AMP-activated protein kinase pathway and by oxidative stress.Cell Signal. 2011;23 (12): 2013-20.
16. Chan-Hui PY,Weaver R.Human mitogen-activated protein kinase kinase kinase mediates the stress-induced activation of mitogen-activated protein kinase cascades.Biochem J. 1998;336 (Pt 3): 599-609.
17. Ge B,Gram H,Di Padova F, et al.MAPKK-independent activation of p38alpha mediated by TAB1-dependent autophosphorylation of p38alpha.Science. 2002;295 (5558): 1291-4.
18. Ninomiya-Tsuji J,Kishimoto K,Hiyama A,Inoue J,Cao Z,Matsumoto K.The kinase TAK1 can activate the NIK-I kappaB as well as the MAP kinase cascade in the IL-1 signalling pathway.Nature. 1999;398 (6724): 252-6.
19. Sato S,Sanjo H,Takeda K, et al.Essential function for the kinase TAK1 in innate and adaptive immune responses.Nat Immunol. 2005;6 (11): 1087-95.
20. Yamaguchi K,Shirakabe K,Shibuya H, et al.Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction.Science. 1995;270 (5244): 2008-11.
21. Ono K,Ohtomo T,Ninomiya-Tsuji J,Tsuchiya M.A dominant negative TAK1 inhibits cellular fibrotic responses induced by TGF-beta.Biochem Biophys Res Commun. 2003;307 (2): 332-7.
22. Kim SI,Kwak JH,Zachariah M,He Y,Wang L,Choi ME.TGF-beta-activated kinase 1 and TAK1-binding protein 1 cooperate to mediate TGF-beta1-induced MKK3-p38 MAPK activation and stimulation of type I collagen.Am J Physiol Renal Physiol. 2007;292 (5): F1471-8.
23. Hocevar BA,Prunier C,Howe PH.Disabled-2 (Dab2) mediates transforming growth factor beta (TGFbeta)-stimulated fibronectin synthesis through TGFbeta-activated kinase 1 and activation of the JNK pathway.J Biol Chem. 2005;280 (27): 25920-7.
24. Wang C,Deng L,Hong M,Akkaraju GR,Inoue J,Chen ZJ.TAK1 is a ubiquitin-dependent kinase of MKK and IKK.Nature. 2001;412 (6844): 346-51.
25. Takaesu G,Surabhi RM,Park KJ,Ninomiya-Tsuji J,Matsumoto K,Gaynor RB.TAK1 is critical for IkappaB kinase-mediated activation of the NF-kappaB pathway.J Mol Biol. 2003;326 (1): 105-15.
26. Yao J,Kim TW,Qin J, et al.Interleukin-1 (IL-1)-induced TAK1-dependent versus MEKK3-dependent NFkappaB activation pathways bifurcate at IL-1 receptor-associated kinase modification.J Biol Chem. 2007;282 (9): 6075-89.
27. Stein B,Yang MX,Young DB, et al.p38-2, a novel mitogen-activated protein kinase with distinct properties.J Biol Chem. 1997;272 (31): 19509-17.
28. Kyriakis JM,Avruch J.Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation.Physiol Rev. 2001;81 (2): 807-69.
29. Beyaert R,Cuenda A,Vanden Berghe W, et al.The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis response to tumor necrosis factor.EMBO J. 1996;15 (8): 1914-23.
30. Huot J,Houle F,Marceau F,Landry J.Oxidative stress-induced actin reorganization mediated by the p38 mitogen-activated protein kinase/heat shock protein 27 pathway in vascular endothelial cells.Circ Res. 1997;80 (3): 383-92.
31. Zhu T,Lobie PE.Janus kinase 2-dependent activation of p38 mitogen-activated protein kinase by growth hormone. Resultant transcriptional activation of ATF-2 and CHOP, cytoskeletal re-organization and mitogenesis.J Biol Chem. 2000;275 (3): 2103-14.
32. Johnson GL,Lapadat R.Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases.Science. 2002;298 (5600): 1911-2.
33. Feng Y,Wen J,Chang CC.p38 Mitogen-activated protein kinase and hematologic malignancies.Arch Pathol Lab Med. 2009;133 (11): 1850-6.
34. Dong C,Davis RJ,Flavell RA.MAP kinases in the immune response.Annu Rev Immunol. 2002;20:55-72.
35. Kumar S,Boehm J,Lee JC.p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases.Nat Rev Drug Discov. 2003;2 (9): 717-26.
36. Chen Z,Gibson TB,Robinson F, et al.MAP kinases.Chem Rev. 2001;101 (8): 2449-76.
37. Olson JM,Hallahan AR.p38 MAP kinase: a convergence point in cancer therapy.Trends Mol Med. 2004;10 (3): 125-9.
38. Wada T,Penninger JM.Mitogen-activated protein kinases in apoptosis regulation.Oncogene. 2004;23 (16): 2838-49.
39. Park JS,Carter S,Reardon DB,Schmidt-Ullrich R,Dent P,Fisher PB.Roles for basal and stimulated p21(Cip-1/WAF1/MDA6) expression and mitogen-activated protein kinase signaling in radiation-induced cell cycle checkpoint control in carcinoma cells.Mol Biol Cell. 1999;10 (12): 4231-46.
40. Park JI,Lee MG,Cho K, et al.Transforming growth factor-beta1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kappaB, JNK, and Ras signaling pathways.Oncogene. 2003;22 (28): 4314-32.
41. Khandrika L,Lieberman R,Koul S, et al.Hypoxia-associated p38 mitogen-activated protein kinase-mediated androgen receptor activation and increased HIF-1alpha levels contribute to emergence of an aggressive phenotype in prostate cancer.Oncogene. 2009;28 (9): 1248-60.
42. Maroni PD,Koul S,Meacham RB,Koul HK.Mitogen activated protein kinase signal transduction pathways in the prostate.Cell Commun Signal. 2004;2 (1): 5.
43. Tsai PW,Shiah SG,Lin MT,Wu CW,Kuo ML.Up-regulation of vascular endothelial growth factor C in breast cancer cells by heregulin-beta 1. A critical role of p38/nuclear factor-kappa B signaling pathway.J Biol Chem. 2003;278 (8): 5750-9.
44. Suarez-Cuervo C,Merrell MA,Watson L, et al.Breast cancer cells with inhibition of p38alpha have decreased MMP-9 activity and exhibit decreased bone metastasis in mice. Clin Exp Metastasis. 2004;21 (6): 525-33.
45. Kumar B,Sinclair J,Khandrika L,Koul S,Wilson S,Koul HK.Differential effects of MAPKs signaling on the growth of invasive bladder cancer cells.Int J Oncol. 2009;34 (6): 1557-64.
46. Kumar B,Koul S,Petersen J, et al.p38 mitogen-activated protein kinase-driven MAPKAPK2 regulates invasion of bladder cancer by modulation of MMP-2 and MMP-9 activity.Cancer Res. 2010;70 (2): 832-41.
47. Iyoda K,Sasaki Y,Horimoto M, et al.Involvement of the p38 mitogen-activated protein kinase cascade in hepatocellular carcinoma.Cancer. 2003;97 (12): 3017-26.
48. Greenberg AK,Basu S,Hu J, et al.Selective p38 activation in human non-small cell lung cancer.Am J Respir Cell Mol Biol. 2002;26 (5): 558-64.
49. Elenitoba-Johnson KS,Jenson SD,Abbott RT, et al.Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy.Proc Natl Acad Sci U S A. 2003;100 (12): 7259-64.
50. Lin Z,Crockett DK,Jenson SD,Lim MS,Elenitoba-Johnson KS.Quantitative proteomic and transcriptional analysis of the response to the p38 mitogen-activated protein kinase inhibitor SB203580 in transformed follicular lymphoma cells.Mol Cell Proteomics. 2004;3 (8): 820-33.
51. Liu RY,Fan C,Liu G,Olashaw NE,Zuckerman KS.Activation of p38 mitogen-activated protein kinase is required for tumor necrosis factor-alpha -supported proliferation of leukemia and lymphoma cell lines.J Biol Chem. 2000;275 (28): 21086-93.
52. Bhowmick NA,Ghiassi M,Bakin A, et al.Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism.Mol Biol Cell. 2001;12 (1): 27-36.
53. Bhowmick NA,Zent R,Ghiassi M,McDonnell M,Moses HL.Integrin beta 1 signaling is necessary for transforming growth factor-beta activation of p38MAPK and epithelial plasticity.J Biol Chem. 2001;276 (50): 46707-13.
54. Cheng TL,Symons M,Jou TS.Regulation of anoikis by Cdc42 and Rac1.Exp Cell Res. 2004;295 (2): 497-511.
55. Bulavin DV,Demidov ON,Saito S, et al.Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity.Nat Genet. 2002;31 (2): 210-5.
56. Brancho D,Tanaka N,Jaeschke A, et al.Mechanism of p38 MAP kinase activation in vivo.Genes Dev. 2003;17 (16): 1969-78.
57. Bulavin DV,Fornace AJ.p38 MAP kinase's emerging role as a tumor suppressor.Adv Cancer Res. 2004;92:95-118.
58. Timofeev O,Lee TY,Bulavin DV.A subtle change in p38 MAPK activity is sufficient to suppress in vivo tumorigenesis.Cell Cycle. 2005;4 (1): 118-20.
59. Ellinger-Ziegelbauer H,Kelly K,Siebenlist U.Cell cycle arrest and reversion of Ras-induced transformation by a conditionally activated form of mitogen-activated protein kinase kinase kinase 3.Mol Cell Biol. 1999;19 (5): 3857-68.
60. Pruitt K,Pruitt WM,Bilter GK,Westwick JK,Der CJ.Raf-independent deregulation of p38 and JNK mitogen-activated protein kinases are critical for Ras transformation.J Biol Chem. 2002;277 (35): 31808-17.
61. Kummer JL,Rao PK,Heidenreich KA.Apoptosis induced by withdrawal of trophic factors is mediated by p38 mitogen-activated protein kinase.J Biol Chem. 1997;272 (33): 20490-4.
62. She QB,Bode AM,Ma WY,Chen NY,Dong Z.Resveratrol-induced activation of p53 and apoptosis is mediated by extracellular-signal-regulated protein kinases and p38 kinase.Cancer Res. 2001;61 (4): 1604-10.
63. Bradham C,McClay DR.p38 MAPK in development and cancer.Cell Cycle. 2006;5 (8): 824-8.
64. Bulavin DV,Kovalsky O,Hollander MC,Fornace AJ.Loss of oncogenic H-ras-induced cell cycle arrest and p38 mitogen-activated protein kinase activation by disruption of Gadd45a.Mol Cell Biol. 2003;23 (11): 3859-71.
65. English JM,Cobb MH.Pharmacological inhibitors of MAPK pathways.Trends Pharmacol Sci. 2002;23 (1): 40-5.
66. Nelson PS,Montgomery B.Cell type-specific analyses for identifying prostate cancer biomarkers.Curr Urol Rep. 2006;7 (1): 57-63.
67. Cronauer MV,Schulz WA,Burchardt T, et al.The androgen receptor in hormone-refractory prostate cancer: relevance of different mechanisms of androgen receptor signaling.Int J Oncol. 2003;23 (4): 1095-102.
68. Guan M,Fousek K,Chow WA.Nelfinavir inhibits regulated intramembrane proteolysis of sterol regulatory element binding protein-1 and activating transcription factor 6 in castration-resistant prostate cancer.FEBS J. 2012;279 (13): 2399-411.
69. Magi-Galluzzi C,Montironi R,Cangi MG,Wishnow K,Loda M.Mitogen-activated protein kinases and apoptosis in PIN.Virchows Arch. 1998;432 (5): 407-13.
70. Royuela M,Arenas MI,Bethencourt FR,Sanchez-Chapado M,Fraile B,Paniagua R.Regulation of proliferation/apoptosis equilibrium by mitogen-activated protein kinases in normal, hyperplastic, and carcinomatous human prostate.Hum Pathol. 2002;33 (3): 299-306.
71. Uzgare AR,Kaplan PJ,Greenberg NM.Differential expression and/or activation of P38MAPK, erk1/2, and jnk during the initiation and progression of prostate cancer.Prostate. 2003;55 (2): 128-39.
72. Heinrich PC,Behrmann I,Haan S,Hermanns HM,Muller-Newen G,Schaper F.Principles of interleukin (IL)-6-type cytokine signalling and its regulation.Biochem J. 2003;374 (Pt 1): 1-20.
73. Tuohimaa P,Lyakhovich A,Aksenov N, et al.Vitamin D and prostate cancer.J Steroid Biochem Mol Biol. 2001;76 (1-5): 125-34.
74. Mehta PB,Robson CN,Neal DE,Leung HY.Keratinocyte growth factor activates p38 MAPK to induce stress fibre formation in human prostate DU145 cells.Oncogene. 2001;20 (38): 5359-65.
75. Kim J,Adam RM,Freeman MR.Activation of the Erk mitogen-activated protein kinase pathway stimulates neuroendocrine differentiation in LNCaP cells independently of cell cycle withdrawal and STAT3 phosphorylation.Cancer Res. 2002;62 (5): 1549-54.
76. Grasso AW,Wen D,Miller CM,Rhim JS,Pretlow TG,Kung HJ.ErbB kinases and NDF signaling in human prostate cancer cells.Oncogene. 1997;15 (22): 2705-16.
77. Stein B,Brady H,Yang MX,Young DB,Barbosa MS.Cloning and characterization of MEK6, a novel member of the mitogen-activated protein kinase kinase cascade.J Biol Chem. 1996;271 (19): 11427-33.
78. Lin JC,Chang SY,Hsieh DS,Lee CF,Yu DS.Modulation of mitogen-activated protein kinase cascades by differentiation-1 protein: acquired drug resistance of hormone independent prostate cancer cells.J Urol. 2005;174 (5): 2022-6.
79. Ricote M,Royuela M,Garcia-Tunon I,Bethencourt FR,Paniagua R,Fraile B.Pro-apoptotic tumor necrosis factor-alpha transduction pathway in normal prostate, benign prostatic hyperplasia and prostatic carcinoma.J Urol. 2003;170 (3): 787-90.
80. Ricote M,Garcia-Tunon I,Bethencourt FR,Fraile B,Paniagua R,Royuela M.Interleukin-1 (IL-1alpha and IL-1beta) and its receptors (IL-1RI, IL-1RII, and IL-1Ra) in prostate carcinoma.Cancer. 2004;100 (7): 1388-96.
81. Ranganathan P,Rangnekar VM.Regulation of cancer cell survival by Par-4.Ann N Y Acad Sci. 2005;1059:76-85.
82. Reynolds AR,Kyprianou N.Growth factor signalling in prostatic growth: significance in tumour development and therapeutic targeting.Br J Pharmacol. 2006;147:S144-52.
83. Tanaka Y,Gavrielides MV,Mitsuuchi Y,Fujii T,Kazanietz MG.Protein kinase C promotes apoptosis in LNCaP prostate cancer cells through activation of p38 MAPK and inhibition of the Akt survival pathway.J Biol Chem. 2003;278 (36): 33753-62.
84. Zoumpourlis V,Papassava P,Linardopoulos S,Gillespie D,Balmain A,Pintzas A.High levels of phosphorylated c-Jun, Fra-1, Fra-2 and ATF-2 proteins correlate with malignant phenotypes in the multistage mouse skin carcinogenesis model.Oncogene. 2000;19 (35): 4011-21.
85. Recio JA,Noonan FP,Takayama H, et al.Ink4a/arf deficiency promotes ultraviolet radiation-induced melanomagenesis.Cancer Res. 2002;62 (22): 6724-30.
86. Huynh H.Induction of apoptosis in rat ventral prostate by finasteride is associated with alteration in MAP kinase pathways and Bcl-2 related family of proteins.Int J Oncol. 2002;20 (6): 1297-303.
87. Xiao D,Qu X,Weber HC.GRP receptor-mediated immediate early gene expression and transcription factor Elk-1 activation in prostate cancer cells.Regul Pept. 2002;109 (1-3): 141-8.
88. Ricote M,Garcia-Tunon I,Bethencourt F, et al.The p38 transduction pathway in prostatic neoplasia.J Pathol. 2006;208 (3): 401-7.
89. Chen L,He HY,Li HM, et al.ERK1/2 and p38 pathways are required for P2Y receptor-mediated prostate cancer invasion. Cancer Lett. 2004;215 (2): 239-47.
90. Shimada K,Nakamura M,Ishida E,Kishi M,Konishi N.Roles of p38- and c-jun NH2-terminal kinase-mediated pathways in 2-methoxyestradiol-induced p53 induction and apoptosis.Carcinogenesis. 2003;24 (6): 1067-75.
91. Permpongkosol S,Wang JD,Takahara S, et al.Anticarcinogenic effect of FTY720 in human prostate carcinoma DU145 cells: modulation of mitogenic signaling, FAK, cell-cycle entry and apoptosis.Int J Cancer. 2002;98 (2): 167-72.
92. Eandi JA,Yang JC,Evans CP.Signal transduction-mediated regulation of urokinase gene expression in human prostate cancer.Biochem Biophys Res Commun. 2001;288 (3): 521-7.
93. Gao N,Jiang BH,Leonard SS, et al.p38 Signaling-mediated hypoxia-inducible factor 1alpha and vascular endothelial growth factor induction by Cr(VI) in DU145 human prostate carcinoma cells.J Biol Chem. 2002;277 (47): 45041-8.
94. Edlund S,Landstrom M,Heldin CH,Aspenstrom P.Transforming growth factor-beta-induced mobilization of actin cytoskeleton requires signaling by small GTPases Cdc42 and RhoA.Mol Biol Cell. 2002;13 (3): 902-14.
95. Aguirre-Ghiso JA,Estrada Y,Liu D,Ossowski L.ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK).Cancer Res. 2003;63 (7): 1684-95.
96. Skjoth IH,Issinger OG.Profiling of signaling molecules in four different human prostate carcinoma cell lines before and after induction of apoptosis.Int J Oncol. 2006;28 (1): 217-29.
97. Koul S,Huang M,Chaturvedi L,Meacham RB,Koul HK.p42/p44 Mitogen-activated protein kinase signal transduction pathway regulates interleukin-6 expression in PC3 cells, a line of hormone-refractory prostate cancer cells.Ann N Y Acad Sci. 2004;1030:253-7.
98. Xu L,Chen S,Bergan RC.MAPKAPK2 and HSP27 are downstream effectors of p38 MAP kinase-mediated matrix metalloproteinase type 2 activation and cell invasion in human prostate cancer.Oncogene. 2006;25 (21): 2987-98.
99. Denkert C,Siegert A,Leclere A,Turzynski A,Hauptmann S.An inhibitor of stress-activated MAP-kinases reduces invasion and MMP-2 expression of malignant melanoma cells.Clin Exp Metastasis. 2002;19 (1): 79-85.
100. Perou CM,Sorlie T,Eisen MB, et al.Molecular portraits of human breast tumours.Nature. 2000;406 (6797): 747-52.
101. del Barco Barrantes I,Nebreda AR.Roles of p38 MAPKs in invasion and metastasis.Biochem Soc Trans. 2012;40 (1): 79-84.
102. Janda E,Lehmann K,Killisch I, et al.Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways.J Cell Biol. 2002;156 (2): 299-313.
103. Smith AP,Verrecchia A,Faga G, et al.A positive role for Myc in TGFbeta-induced Snail transcription and epithelial-to-mesenchymal transition.Oncogene. 2009;28 (3): 422-30.
104. Yu M,Smolen GA,Zhang J, et al.A developmentally regulated inducer of EMT, LBX1, contributes to breast cancer progression.Genes Dev. 2009;23 (15): 1737-42.
105. Dhasarathy A,Kajita M,Wade PA.The transcription factor snail mediates epithelial to mesenchymal transitions by repression of estrogen receptor-alpha.Mol Endocrinol. 2007;21 (12): 2907-18.
106. Horn G,Gaziel A,Wreschner DH,Smorodinsky NI,Ehrlich M.ERK and PI3K regulate different aspects of the epithelial to mesenchymal transition of mammary tumor cells induced by truncated MUC1.Exp Cell Res. 2009;315 (8): 1490-504.
107. Lee MK,Pardoux C,Hall MC, et al.TGF-beta activates Erk MAP kinase signalling through direct phosphorylation of ShcA.EMBO J. 2007;26 (17): 3957-67.
108. Takekawa M,Tatebayashi K,Itoh F,Adachi M,Imai K,Saito H.Smad-dependent GADD45beta expression mediates delayed activation of p38 MAP kinase by TGF-beta.EMBO J. 2002;21 (23): 6473-82.
109. Kim ES,Kim MS,Moon A.TGF-beta-induced upregulation of MMP-2 and MMP-9 depends on p38 MAPK, but not ERK signaling in MCF10A human breast epithelial cells.Int J Oncol. 2004;25 (5): 1375-82.
110. Kim MS,Lee EJ,Kim HR,Moon A.p38 kinase is a key signaling molecule for H-Ras-induced cell motility and invasive phenotype in human breast epithelial cells.Cancer Res. 2003;63 (17): 5454-61.
111. Yong HY,Hwang JS,Son H, et al.Identification of H-Ras-specific motif for the activation of invasive signaling program in human breast epithelial cells.Neoplasia. 2011;13 (2): 98-107.
112. Nick JA,Avdi NJ,Young SK, et al.Common and distinct intracellular signaling pathways in human neutrophils utilized by platelet activating factor and FMLP.J Clin Invest. 1997;99 (5): 975-86.
113. Zhang Y,Neo SY,Han J,Yaw LP,Lin SC.RGS16 attenuates galphaq-dependent p38 mitogen-activated protein kinase activation by platelet-activating factor.J Biol Chem. 1999;274 (5): 2851-7.
114. Haagenson KK,Wu GS.The role of MAP kinases and MAP kinase phosphatase-1 in resistance to breast cancer treatment.Cancer Metastasis Rev. 2010;29 (1): 143-9.
115. Zhou JY,Liu Y,Wu GS.The role of mitogen-activated protein kinase phosphatase-1 in oxidative damage-induced cell death.Cancer Res. 2006;66 (9): 4888-94.
116. Han J,Jiang Y,Li Z,Kravchenko VV,Ulevitch RJ.Activation of the transcription factor MEF2C by the MAP kinase p38 in inflammation.Nature. 1997;386 (6622): 296-9.
117. Wang XZ,Ron D.Stress-induced phosphorylation and activation of the transcription factor CHOP (GADD153) by p38 MAP kinase.Science. 1996;272 (5266): 1347-9.
118. Yang SH,Galanis A,Sharrocks AD.Targeting of p38 mitogen-activated protein kinases to MEF2 transcription factors.Mol Cell Biol. 1999;19 (6): 4028-38.
119. Vermeulen L,De Wilde G,Van Damme P,Vanden Berghe W,Haegeman G.Transcriptional activation of the NF-kappaB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1).EMBO J. 2003;22 (6): 1313-24.
120. Song H,Ki SH,Kim SG,Moon A.Activating transcription factor 2 mediates matrix metalloproteinase-2 transcriptional activation induced by p38 in breast epithelial cells.Cancer Res. 2006;66 (21): 10487-96.
121. Campbell J,Ciesielski CJ,Hunt AE, et al.A novel mechanism for TNF-alpha regulation by p38 MAPK: involvement of NF-kappa B with implications for therapy in rheumatoid arthritis.J Immunol. 2004;173 (11): 6928-37.
122. Carter AB,Knudtson KL,Monick MM,Hunninghake GW.The p38 mitogen-activated protein kinase is required for NF-kappaB-dependent gene expression. The role of TATA-binding protein (TBP).J Biol Chem. 1999;274 (43): 30858-63.
123. Timoshenko AV,Chakraborty C,Wagner GF,Lala PK.COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer.Br J Cancer. 2006;94 (8): 1154-63.
124. Morooka H,Bonventre JV,Pombo CM,Kyriakis JM,Force T.Ischemia and reperfusion enhance ATF-2 and c-Jun binding to cAMP response elements and to an AP-1 binding site from the c-jun promoter.J Biol Chem. 1995;270 (50): 30084-92.
125. Zhao M,New L,Kravchenko VV, et al.Regulation of the MEF2 family of transcription factors by p38.Mol Cell Biol. 1999;19 (1): 21-30.
126. Huang S,New L,Pan Z,Han J,Nemerow GR.Urokinase plasminogen activator/urokinase-specific surface receptor expression and matrix invasion by breast cancer cells requires constitutive p38alpha mitogen-activated protein kinase activity.J Biol Chem. 2000;275 (16): 12266-72.
127. Han YC,Zeng XX,Wang R,Zhao Y,Li BL,Song M.Correlation of p38 mitogen-activated protein kinase signal transduction pathway to uPA expression in breast cancer.Ai Zheng. 2007;26 (1): 48-53.
128. Han Q,Leng J,Bian D, et al.Rac1-MKK3-p38-MAPKAPK2 pathway promotes urokinase plasminogen activator mRNA stability in invasive breast cancer cells.J Biol Chem. 2002;277 (50): 48379-85.
129. Galliher AJ,Schiemann WP.Src phosphorylates Tyr284 in TGF-beta type II receptor and regulates TGF-beta stimulation of p38 MAPK during breast cancer cell proliferation and invasion.Cancer Res. 2007;67 (8): 3752-8.
130. Sossey-Alaoui K,Ranalli TA,Li X,Bakin AV,Cowell JK.WAVE3 promotes cell motility and invasion through the regulation of MMP-1, MMP-3, and MMP-9 expression.Exp Cell Res. 2005;308 (1): 135-45.
131. Gutierrez MC,Detre S,Johnston S, et al.Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase.J Clin Oncol. 2005;23 (11): 2469-76.
132. Lee H,Bai W.Regulation of estrogen receptor nuclear export by ligand-induced and p38-mediated receptor phosphorylation.Mol Cell Biol. 2002;22 (16): 5835-45.
133. Underwood DC,Osborn RR,Kotzer CJ, et al.SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence.J Pharmacol Exp Ther. 2000;293 (1): 281-8.
134. Shin I,Kim S,Song H,Kim HR,Moon A.H-Ras-specific activation of Rac-MKK3/6-p38 pathway: its critical role in invasion and migration of breast epithelial cells.J Biol Chem. 2005;280 (15): 14675-83.
135. Liotta LA,Steeg PS,Stetler-Stevenson WG.Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation.Cell. 1991;64 (2): 327-36.
136. Johansson N,Ala-aho R,Uitto V, et al.Expression of collagenase-3 (MMP-13) and collagenase-1 (MMP-1) by transformed keratinocytes is dependent on the activity of p38 mitogen-activated protein kinase.J Cell Sci. 2000;113 (Pt 2): 227-35.
137. Simon C,Simon M,Vucelic G, et al.The p38 SAPK pathway regulates the expression of the MMP-9 collagenase via AP-1-dependent promoter activation. Exp Cell Res. 2001;271 (2): 344-55.
138. Simon C,Goepfert H,Boyd D.Inhibition of the p38 mitogen-activated protein kinase by SB 203580 blocks PMA-induced Mr 92,000 type IV collagenase secretion and in vitro invasion.Cancer Res. 1998;58 (6): 1135-9.
139. Reunanen N,Li SP,Ahonen M,Foschi M,Han J,Kahari VM.Activation of p38 alpha MAPK enhances collagenase-1 (matrix metalloproteinase (MMP)-1) and stromelysin-1 (MMP-3) expression by mRNA stabilization.J Biol Chem. 2002;277 (35): 32360-8.
140. Rust W,Kingsley K,Petnicki T,Padmanabhan S,Carper SW,Plopper GE.Heat shock protein 27 plays two distinct roles in controlling human breast cancer cell migration on laminin-5.Mol Cell Biol Res Commun. 1999;1 (3): 196-202.
141. Yao J,Xiong S,Klos K, et al.Multiple signaling pathways involved in activation of matrix metalloproteinase-9 (MMP-9) by heregulin-beta1 in human breast cancer cells.Oncogene. 2001;20 (56): 8066-74.
142. Nguyen TH,Mustafa FB,Pervaiz S,Ng FS,Lim LH.ERK1/2 activation is required for resveratrol-induced apoptosis in MDA-MB-231 cells.Int J Oncol. 2008;33 (1): 81-92.
143. Yu W,Sanders BG,Kline K.RRR-alpha-tocopheryl succinate-induced apoptosis of human breast cancer cells involves Bax translocation to mitochondria.Cancer Res. 2003;63 (10): 2483-91.
144. Davidson B,Konstantinovsky S,Nielsen S, et al.Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients: a novel model for tumor progression.Clin Cancer Res. 2004;10 (21): 7335-46.
145. Konstantinovsky S,Nielsen S,Vyberg M, et al.Angiogenic molecule expression is downregulated in effusions from breast cancer patients.Breast Cancer Res Treat. 2005;94 (1): 71-80.
146. Davidson B,Reich R,Lazarovici P,Ann Florenes V,Nielsen S,Nesland JM.Altered expression and activation of the nerve growth factor receptors TrkA and p75 provide the first evidence of tumor progression to effusion in breast carcinoma.Breast Cancer Res Treat. 2004;83 (2): 119-28.
147. Boutros T,Chevet E,Metrakos P.Mitogen-activated protein (MAP) kinase/MAP kinase phosphatase regulation: roles in cell growth, death, and cancer.Pharmacol Rev. 2008;60 (3): 261-310.
148. Sengupta N,Siddiqui E,Mumtaz FH.Cancers of the bladder.J R Soc Promot Health. 2004;124 (5): 228-9.
149. Oosterlinck W,Lobel B,Jakse G, et al.Guidelines on bladder cancer.Eur Urol. 2002;41 (2): 105-12.
150. Tolley DA,Parmar MK,Grigor KM, et al.The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up.J Urol. 1996;155 (4): 1233-8.
151. Feng GJ,Goodridge HS,Harnett MM, et al.Extracellular signal-related kinase (ERK) and p38 mitogen-activated protein (MAP) kinases differentially regulate the lipopolysaccharide-mediated induction of inducible nitric oxide synthase and IL-12 in macrophages: leishmania phosphoglycans subvert macrophage IL-12 production by targeting ERK MAP kinase.J Immunol. 1999;163 (12): 6403-12.
152. Scherle PA,Jones EA,Favata MF, et al.Inhibition of MAP kinase kinase prevents cytokine and prostaglandin E2 production in lipopolysaccharide-stimulated monocytes.J Immunol. 1998;161 (10): 5681-6.
153. Valledor AF,Comalada M,Xaus J,Celada A.The differential time-course of extracellular-regulated kinase activity correlates with the macrophage response toward proliferation or activation.J Biol Chem. 2000;275 (10): 7403-9.
154. Shan X,Hu A,Veler H, et al.Regulation of Toll-like receptor 4-induced proasthmatic changes in airway smooth muscle function by opposing actions of ERK1/2 and p38 MAPK signaling.Am J Physiol Lung Cell Mol Physiol. 2006;291 (3): L324-33.
155. Yokoyama T,Komori A,Nakamura M, et al.Human intrahepatic biliary epithelial cells function in innate immunity by producing IL-6 and IL-8 via the TLR4-NF-kappaB and -MAPK signaling pathways.Liver Int. 2006;26 (4): 467-76.
156. Seguchi T,Yokokawa K,Sugao H,Nakano E,Sonoda T,Okuyama A.Interleukin-6 activity in urine and serum in patients with bladder carcinoma.J Urol. 1992;148 (3): 791-4.
157. Cardillo MR,Sale P,Di Silverio F.Heat shock protein-90, IL-6 and IL-10 in bladder cancer.Anticancer Res. 2000;20 (6B): 4579-83.
158. Okamoto M,Hattori K,Oyasu R.Interleukin-6 functions as an autocrine growth factor in human bladder carcinoma cell lines in vitro.Int J Cancer. 1997;72 (1): 149-54.
159. Horwood NJ,Page TH,McDaid JP, et al.Bruton's tyrosine kinase is required for TLR2 and TLR4-induced TNF, but not IL-6, production.J Immunol. 2006;176 (6): 3635-41.
160. Davies B,Waxman J,Wasan H, et al.Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion.Cancer Res. 1993;53 (22): 5365-9.
161. Nutt JE,Durkan GC,Mellon JK,Lunec J.Matrix metalloproteinases (MMPs) in bladder cancer: the induction of MMP9 by epidermal growth factor and its detection in urine.BJU Int. 2003;91 (1): 99-104.
162. Ozdemir E,Kakehi Y,Okuno H,Yoshida O.Role of matrix metalloproteinase-9 in the basement membrane destruction of superficial urothelial carcinomas.J Urol. 1999;161 (4): 1359-63.
163. Cohen M,Meisser A,Haenggeli L,Bischof P.Involvement of MAPK pathway in TNF-alpha-induced MMP-9 expression in human trophoblastic cells.Mol Hum Reprod. 2006;12 (4): 225-32.
164. Zipper LM,Mulcahy RT.Inhibition of ERK and p38 MAP kinases inhibits binding of Nrf2 and induction of GCS genes.Biochem Biophys Res Commun. 2000;278 (2): 484-92.
165. Alam J,Wicks C,Stewart D, et al.Mechanism of heme oxygenase-1 gene activation by cadmium in MCF-7 mammary epithelial cells. Role of p38 kinase and Nrf2 transcription factor.J Biol Chem. 2000;275 (36): 27694-702.
166. Keum YS,Yu S,Chang PP, et al.Mechanism of action of sulforaphane: inhibition of p38 mitogen-activated protein kinase isoforms contributing to the induction of antioxidant response element-mediated heme oxygenase-1 in human hepatoma HepG2 cells.Cancer Res. 2006;66 (17): 8804-13.
167. Owuor ED,Kong AN.Antioxidants and oxidants regulated signal transduction pathways.Biochem Pharmacol. 2002;64 (5-6): 765-70.
168. Buytaert E,Callewaert G,Hendrickx N, et al.Role of endoplasmic reticulum depletion and multidomain proapoptotic BAX and BAK proteins in shaping cell death after hypericin-mediated photodynamic therapy.FASEB J. 2006;20 (6): 756-8.
169. Assefa Z,Vantieghem A,Declercq W, et al.The activation of the c-Jun N-terminal kinase and p38 mitogen-activated protein kinase signaling pathways protects HeLa cells from apoptosis following photodynamic therapy with hypericin.J Biol Chem. 1999;274 (13): 8788-96.
170. Hendrickx N,Volanti C,Moens U, et al.Up-regulation of cyclooxygenase-2 and apoptosis resistance by p38 MAPK in hypericin-mediated photodynamic therapy of human cancer cells.J Biol Chem. 2003;278 (52): 52231-9.
171. Zarubin T,Han J.Activation and signaling of the p38 MAP kinase pathway.Cell Res. 2005;15 (1): 11-8.
172. Lee TJ,Sartor O,Luftig RB,Koochekpour S.Saposin C promotes survival and prevents apoptosis via PI3K/Akt-dependent pathway in prostate cancer cells.Mol Cancer. 2004;3:31.
173. Itoh K,Ishii T,Wakabayashi N,Yamamoto M.Regulatory mechanisms of cellular response to oxidative stress.Free Radic Res. 1999;31 (4): 319-24.
174. Kocanova S,Buytaert E,Matroule JY, et al.Induction of heme-oxygenase 1 requires the p38MAPK and PI3K pathways and suppresses apoptotic cell death following hypericin-mediated photodynamic therapy.Apoptosis. 2007;12 (4): 731-41.
175. Bostrom PJ,Ravanti L,Reunanen N, et al.Expression of collagenase-3 (matrix metalloproteinase-13) in transitional-cell carcinoma of the urinary bladder.Int J Cancer. 2000;88 (3): 417-23.
176. Buytaert E,Matroule JY,Durinck S, et al.Molecular effectors and modulators of hypericin-mediated cell death in bladder cancer cells.Oncogene. 2008;27 (13): 1916-29.
177. Romanenko A,Morimura K,Wanibuchi H, et al.Urinary bladder lesions induced by persistent chronic low-dose ionizing radiation.Cancer Sci. 2003;94 (4): 328-33.
178. Capon DJ,Chen EY,Levinson AD,Seeburg PH,Goeddel DV.Complete nucleotide sequences of the T24 human bladder carcinoma oncogene and its normal homologue.Nature. 1983;302 (5903): 33-7.
179. Aaltonen V,Bostrom PJ,Soderstrom KO, et al.Urinary bladder transitional cell carcinogenesis is associated with down-regulation of NF1 tumor suppressor gene in vivo and in vitro.Am J Pathol. 1999;154 (3): 755-65.
180. Larrea E,Garcia N,Qian C,Civeira MP,Prieto J.Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C.Hepatology. 1996;23 (2): 210-7.
181. Kaplanski G,Farnarier C,Payan MJ,Bongrand P,Durand JM.Increased levels of soluble adhesion molecules in the serum of patients with hepatitis C. Correlation with cytokine concentrations and liver inflammation and fibrosis.Dig Dis Sci. 1997;42 (11): 2277-84.
182. Rosette C,Karin M.Ultraviolet light and osmotic stress: activation of the JNK cascade through multiple growth factor and cytokine receptors.Science. 1996;274 (5290): 1194-7.
183. Xia Z,Dickens M,Raingeaud J,Davis RJ,Greenberg ME.Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis.Science. 1995;270 (5240): 1326-31.
184. Ichijo H,Nishida E,Irie K, et al.Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways.Science. 1997;275 (5296): 90-4.
185. Chen Z,Seimiya H,Naito M, et al.ASK1 mediates apoptotic cell death induced by genotoxic stress.Oncogene. 1999;18 (1): 173-80.
186. MacFarlane M,Cohen GM,Dickens M.JNK (c-Jun N-terminal kinase) and p38 activation in receptor-mediated and chemically-induced apoptosis of T-cells: differential requirements for caspase activation.Biochem J. 2000;348 (Pt 1): 93-101.
187. Sakamoto H,Mashima T,Sato S,Hashimoto Y,Yamori T,Tsuruo T.Selective activation of apoptosis program by S-p-bromobenzylglutathione cyclopentyl diester in glyoxalase I-overexpressing human lung cancer cells.Clin Cancer Res. 2001;7 (8): 2513-8.
188. Verheij M,Bose R,Lin XH, et al.Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis.Nature. 1996;380 (6569): 75-9.
189. Enslen H,Raingeaud J,Davis RJ.Selective activation of p38 mitogen-activated protein (MAP) kinase isoforms by the MAP kinase kinases MKK3 and MKK6.J Biol Chem. 1998;273 (3): 1741-8.
190. Butterfield L,Storey B,Maas L,Heasley LE.c-Jun NH2-terminal kinase regulation of the apoptotic response of small cell lung cancer cells to ultraviolet radiation.J Biol Chem. 1997;272 (15): 10110-6.
191. Zanke BW,Boudreau K,Rubie E, et al.The stress-activated protein kinase pathway mediates cell death following injury induced by cis-platinum, UV irradiation or heat.Curr Biol. 1996;6 (5): 606-13.
192. Brenner B,Koppenhoefer U,Weinstock C,Linderkamp O,Lang F,Gulbins E.Fas- or ceramide-induced apoptosis is mediated by a Rac1-regulated activation of Jun N-terminal kinase/p38 kinases and GADD153.J Biol Chem. 1997;272 (35): 22173-81.
193. Goillot E,Raingeaud J,Ranger A, et al.Mitogen-activated protein kinase-mediated Fas apoptotic signaling pathway.Proc Natl Acad Sci U S A. 1997;94 (7): 3302-7.
194. Li H,Zhu H,Xu CJ,Yuan J.Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis.Cell. 1998;94 (4): 491-501.
195. Farley N,Pedraza-Alva G,Serrano-Gomez D, et al.p38 mitogen-activated protein kinase mediates the Fas-induced mitochondrial death pathway in CD8+ T cells.Mol Cell Biol. 2006;26 (6): 2118-29.
196. Hatai T,Matsuzawa A,Inoshita S, et al.Execution of apoptosis signal-regulating kinase 1 (ASK1)-induced apoptosis by the mitochondria-dependent caspase activation.J Biol Chem. 2000;275 (34): 26576-81.
197. Teng DH,Perry WL,Hogan JK, et al.Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor.Cancer Res. 1997;57 (19): 4177-82.
198. Kang JS,Kim HM,Choi IY, et al.DBM1285 suppresses tumor necrosis factor alpha production by blocking p38 mitogen-activated protein kinase/mitogen-activated protein kinase-activated protein kinase 2 signaling pathway.J Pharmacol Exp Ther. 2010;334 (2): 657-64.
199. Shin EC,Shin JS,Park JH,Kim JJ,Kim H,Kim SJ.Expression of Fas-related genes in human hepatocellular carcinomas.Cancer Lett. 1998;134 (2): 155-62.
200. Loda M,Capodieci P,Mishra R, et al.Expression of mitogen-activated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis.Am J Pathol. 1996;149 (5): 1553-64.
201. Kikuchi K,Kitamura K,Kakinoki Y, et al.Gene expressions and activities of protein phosphatases 1 alpha, 2A and 2C in hepatocarcinogenesis and regeneration after partial hepatectomy.Cancer Detect Prev. 1997;21 (1): 36-43.
202. Seufferlein T,Seckl MJ,Schwarz E, et al.Mechanisms of nordihydroguaiaretic acid-induced growth inhibition and apoptosis in human cancer cells.Br J Cancer. 2002;86 (7): 1188-96.
203. Wu J,Suzuki H,Akhand AA,Zhou YW,Hossain K,Nakashima I.Modes of activation of mitogen-activated protein kinases and their roles in cepharanthine-induced apoptosis in human leukemia cells.Cell Signal. 2002;14 (6): 509-15.
204. Lee JC,Kassis S,Kumar S,Badger A,Adams JL.p38 mitogen-activated protein kinase inhibitors-mechanisms and therapeutic potentials.Pharmacol Ther. 1999;82 (2-3): 389-97.
205. Barnes PJ.Novel approaches and targets for treatment of chronic obstructive pulmonary disease.Am J Respir Crit Care Med. 1999;160 (5 Pt 2): S72-9.
206. Lee JC,Kumar S,Griswold DE,Underwood DC,Votta BJ,Adams JL.Inhibition of p38 MAP kinase as a therapeutic strategy.Immunopharmacology. 2000;47 (2-3): 185-201.
207. Barnes PJ,Chung KF,Page CP.Inflammatory mediators of asthma: an update.Pharmacol Rev. 1998;50 (4): 515-96.
208. Tamura DY,Moore EE,Johnson JL,Zallen G,Aiboshi J,Silliman CC.p38 mitogen-activated protein kinase inhibition attenuates intercellular adhesion molecule-1 up-regulation on human pulmonary microvascular endothelial cells.Surgery. 1998;124 (2): 403-7.
209. Scott PH,Paul A,Belham CM, et al.Hypoxic stimulation of the stress-activated protein kinases in pulmonary artery fibroblasts.Am J Respir Crit Care Med. 1998;158 (3): 958-62.
210. Hashimoto S,Matsumoto K,Gon Y,Nakayama T,Takeshita I,Horie T.Hyperosmolarity-induced interleukin-8 expression in human bronchial epithelial cells through p38 mitogen-activated protein kinase.Am J Respir Crit Care Med. 1999;159 (2): 634-40.
211. Kankaanranta H,De Souza PM,Barnes PJ,Salmon M,Giembycz MA,Lindsay MA.SB 203580, an inhibitor of p38 mitogen-activated protein kinase, enhances constitutive apoptosis of cytokine-deprived human eosinophils.J Pharmacol Exp Ther. 1999;290 (2): 621-8.
212. Underwood DC,Osborn RR,Bochnowicz S, et al.SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung.Am J Physiol Lung Cell Mol Physiol. 2000;279 (5): L895-902.
213. Marshall LA,Hansbury MJ,Bolognese BJ,Gum RJ,Young PR,Mayer RJ.Inhibitors of the p38 mitogen-activated kinase modulate IL-4 induction of low affinity IgE receptor (CD23) in human monocytes.J Immunol. 1998;161 (11): 6005-13.
214. Bracke M,Coffer PJ,Lammers JW,Koenderman L.Analysis of signal transduction pathways regulating cytokine-mediated Fc receptor activation on human eosinophils.J Immunol. 1998;161 (12): 6768-74.
215. Ulich TR,Yin SM,Guo KZ,del Castillo J,Eisenberg SP,Thompson RC.The intratracheal administration of endotoxin and cytokines. III. The interleukin-1 (IL-1) receptor antagonist inhibits endotoxin- and IL-1-induced acute inflammation.Am J Pathol. 1991;138 (3): 521-4.
216. Strieter RM,Kunkel SL.Acute lung injury: the role of cytokines in the elicitation of neutrophils.J Investig Med. 1994;42 (4): 640-51.
217. Koh Y,Hybertson BM,Jepson EK,Repine JE.Tumor necrosis factor induced acute lung leak in rats: less than with interleukin-1.Inflammation. 1996;20 (5): 461-9.
218. Mulligan MS,Vaporciyan AA,Miyasaka M,Tamatani T,Ward PA.Tumor necrosis factor alpha regulates in vivo intrapulmonary expression of ICAM-1.Am J Pathol. 1993;142 (6): 1739-49.
219. Lee JC,Adams JL.Inhibitors of serine/threonine kinases.Curr Opin Biotechnol. 1995;6 (6): 657-61.
220. Lee JC,Badger AM,Griswold DE, et al.Bicyclic imidazoles as a novel class of cytokine biosynthesis inhibitors.Ann N Y Acad Sci. 1993;696:149-70.
221. Lee JC,Laydon JT,McDonnell PC, et al.A protein kinase involved in the regulation of inflammatory cytokine biosynthesis.Nature. 1994;372 (6508): 739-46.
222. Young P,McDonnell P,Dunnington D,Hand A,Laydon J,Lee J.Pyridinyl imidazoles inhibit IL-1 and TNF production at the protein level.Agents Actions. 1993;:.
223. Davis RJ.Transcriptional regulation by MAP kinases.Mol Reprod Dev. 1995;42 (4): 459-67.
224. Prichett W,Hand A,Sheilds J,Dunnington D.Mechanism of action of bicyclic imidazoles defines a translational regulatory pathway for tumor necrosis factor alpha.J Inflamm. 1995;45 (2): 97-105.
225. O'Leary EC,Marder P,Zuckerman SH.Glucocorticoid effects in an endotoxin-induced rat pulmonary inflammation model: differential effects on neutrophil influx, integrin expression, and inflammatory mediators.Am J Respir Cell Mol Biol. 1996;15 (1): 97-106.
226. Ulich TR,Yin S,Remick DG,Russell D,Eisenberg SP,Kohno T.Intratracheal administration of endotoxin and cytokines. IV. The soluble tumor necrosis factor receptor type I inhibits acute inflammation.Am J Pathol. 1993;142 (5): 1335-8.
227. Wesselius LJ,Smirnov IM,O'Brien-Ladner AR,Nelson ME.Synergism of intratracheally administered tumor necrosis factor with interleukin-1 in the induction of lung edema in rats.J Lab Clin Med. 1995;125 (5): 618-25.
228. Fuchs HJ,Debs R,Patton JS,Liggitt HD.The pattern of lung injury induced after pulmonary exposure to tumor necrosis factor-alpha depends on the route of administration.Diagn Microbiol Infect Dis. 1990;13 (5): 397-404.
229. Kolls JK,Lei D,Nelson S,Summer WR,Greenberg S,Beutler B.Adenovirus-mediated blockade of tumor necrosis factor in mice protects against endotoxic shock yet impairs pulmonary host defense.J Infect Dis. 1995;171 (3): 570-5.
230. Skerrett SJ,Martin TR,Chi EY,Peschon JJ,Mohler KM,Wilson CB.Role of the type 1 TNF receptor in lung inflammation after inhalation of endotoxin or Pseudomonas aeruginosa.Am J Physiol. 1999;276 (5): L715-27.
231. Carter AB,Monick MM,Hunninghake GW.Both Erk and p38 kinases are necessary for cytokine gene transcription.Am J Respir Cell Mol Biol. 1999;20 (4): 751-8.
232. Jiang Y,Chen C,Li Z, et al.Characterization of the structure and function of a new mitogen-activated protein kinase (p38beta).J Biol Chem. 1996;271 (30): 17920-6.
233. Lechner C,Zahalka MA,Giot JF,Moller NP,Ullrich A.ERK6, a mitogen-activated protein kinase involved in C2C12 myoblast differentiation.Proc Natl Acad Sci U S A. 1996;93 (9): 4355-9.
234. Wang XS,Diener K,Manthey CL, et al.Molecular cloning and characterization of a novel p38 mitogen-activated protein kinase.J Biol Chem. 1997;272 (38): 23668-74.
235. Jiang Y,Gram H,Zhao M, et al.Characterization of the structure and function of the fourth member of p38 group mitogen-activated protein kinases, p38delta.J Biol Chem. 1997;272 (48): 30122-8.
236. Hale KK,Trollinger D,Rihanek M,Manthey CL.Differential expression and activation of p38 mitogen-activated protein kinase alpha, beta, gamma, and delta in inflammatory cell lineages.J Immunol. 1999;162 (7): 4246-52.
237. Nick JA,Avdi NJ,Young SK, et al.Selective activation and functional significance of p38alpha mitogen-activated protein kinase in lipopolysaccharide-stimulated neutrophils.J Clin Invest. 1999;103 (6): 851-8.
238. Hu MC,Wang YP,Mikhail A,Qiu WR,Tan TH.Murine p38-delta mitogen-activated protein kinase, a developmentally regulated protein kinase that is activated by stress and proinflammatory cytokines.J Biol Chem. 1999;274 (11): 7095-102.
239. Kumar S,McDonnell PC,Gum RJ,Hand AT,Lee JC,Young PR.Novel homologues of CSBP/p38 MAP kinase: activation, substrate specificity and sensitivity to inhibition by pyridinyl imidazoles.Biochem Biophys Res Commun. 1997;235 (3): 533-8.
240. Foey AD,Parry SL,Williams LM,Feldmann M,Foxwell BM,Brennan FM.Regulation of monocyte IL-10 synthesis by endogenous IL-1 and TNF-alpha: role of the p38 and p42/44 mitogen-activated protein kinases.J Immunol. 1998;160 (2): 920-8.
241. Ajizian SJ,English BK,Meals EA.Specific inhibitors of p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways block inducible nitric oxide synthase and tumor necrosis factor accumulation in murine macrophages stimulated with lipopolysaccharide and interferon-gamma.J Infect Dis. 1999;179 (4): 939-44.
242. Hui L,Bakiri L,Stepniak E,Wagner EF.p38alpha: a suppressor of cell proliferation and tumorigenesis.Cell Cycle. 2007;6 (20): 2429-33.
243. Thornton TM,Rincon M.Non-classical p38 map kinase functions: cell cycle checkpoints and survival.Int J Biol Sci. 2009;5 (1): 44-51.
244. Tortora G,Bianco R,Daniele G, et al.Overcoming resistance to molecularly targeted anticancer therapies: rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies.Drug Resist Updat. 2007;10 (3): 81-100.
245. Oeckinghaus A,Ghosh S.The NF-kappaB family of transcription factors and its regulation.Cold Spring Harb Perspect Biol. 2009;1 (4): a000034.
246. Clark AR,Dean JL,Saklatvala J.Post-transcriptional regulation of gene expression by mitogen-activated protein kinase p38.FEBS Lett. 2003;546 (1): 37-44.
247. Kim C,Sano Y,Todorova K, et al.The kinase p38 alpha serves cell type-specific inflammatory functions in skin injury and coordinates pro- and anti-inflammatory gene expression.Nat Immunol. 2008;9 (9): 1019-27.
248. Kang YJ,Chen J,Otsuka M, et al.Macrophage deletion of p38alpha partially impairs lipopolysaccharide-induced cellular activation.J Immunol. 2008;180 (7): 5075-82.
249. Beardmore VA,Hinton HJ,Eftychi C, et al.Generation and characterization of p38beta (MAPK11) gene-targeted mice.Mol Cell Biol. 2005;25 (23): 10454-64.
250. O'Keefe SJ,Mudgett JS,Cupo S, et al.Chemical genetics define the roles of p38alpha and p38beta in acute and chronic inflammation.J Biol Chem. 2007;282 (48): 34663-71.
251. Pourgholami MH,Morris DL.Inhibitors of vascular endothelial growth factor in cancer.Cardiovasc Hematol Agents Med Chem. 2008;6 (4): 343-7.
252. Koodie L,Ramakrishnan S,Roy S.Morphine suppresses tumor angiogenesis through a HIF-1alpha/p38MAPK pathway.Am J Pathol. 2010;177 (2): 984-97.
253. Loesch M,Chen G.The p38 MAPK stress pathway as a tumor suppressor or more?.Front Biosci. 2008;13:3581-93.
254. Junttila MR,Ala-Aho R,Jokilehto T, et al.p38alpha and p38delta mitogen-activated protein kinase isoforms regulate invasion and growth of head and neck squamous carcinoma cells.Oncogene. 2007;26 (36): 5267-79.
255. Hickson JA,Huo D,Vander Griend DJ,Lin A,Rinker-Schaeffer CW,Yamada SD.The p38 kinases MKK4 and MKK6 suppress metastatic colonization in human ovarian carcinoma.Cancer Res. 2006;66 (4): 2264-70.
256. Dreissigacker U,Mueller MS,Unger M, et al.Oncogenic K-Ras down-regulates Rac1 and RhoA activity and enhances migration and invasion of pancreatic carcinoma cells through activation of p38.Cell Signal. 2006;18 (8): 1156-68.
257. McMullen ME,Bryant PW,Glembotski CC,Vincent PA,Pumiglia KM.Activation of p38 has opposing effects on the proliferation and migration of endothelial cells.J Biol Chem. 2005;280 (22): 20995-1003.
258. Kobayashi M,Nishita M,Mishima T,Ohashi K,Mizuno K.MAPKAPK-2-mediated LIM-kinase activation is critical for VEGF-induced actin remodeling and cell migration.EMBO J. 2006;25 (4): 713-26.
259. Koul H,Khandrika L.Signaltransduction targets in prostate cancer.Curr Signal Transduction Ther. 2008;3 (2): 112-28.
260. Adams RH,Porras A,Alonso G, et al.Essential role of p38alpha MAP kinase in placental but not embryonic cardiovascular development.Mol Cell. 2000;6 (1): 109-16.
261. Mudgett JS,Ding J,Guh-Siesel L, et al.Essential role for p38alpha mitogen-activated protein kinase in placental angiogenesis.Proc Natl Acad Sci U S A. 2000;97 (19): 10454-9.
262. Sabio G,Arthur JS,Kuma Y, et al.p38gamma regulates the localisation of SAP97 in the cytoskeleton by modulating its interaction with GKAP.EMBO J. 2005;24 (6): 1134-45.
263. Sumara G,Formentini I,Collins S, et al.Regulation of PKD by the MAPK p38delta in insulin secretion and glucose homeostasis.Cell. 2009;136 (2): 235-48.
264. Schindler EM,Hindes A,Gribben EL, et al.p38delta Mitogen-activated protein kinase is essential for skin tumor development in mice.Cancer Res. 2009;69 (11): 4648-55.
265. Demuth T,Reavie LB,Rennert JL, et al.MAP-ing glioma invasion: mitogen-activated protein kinase kinase 3 and p38 drive glioma invasion and progression and predict patient survival.Mol Cancer Ther. 2007;6 (4): 1212-22.
266. Esteva FJ,Sahin AA,Smith TL, et al.Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma.Cancer. 2004;100 (3): 499-506.
267. Pomerance M,Quillard J,Chantoux F,Young J,Blondeau JP.High-level expression, activation, and subcellular localization of p38-MAP kinase in thyroid neoplasms.J Pathol. 2006;209 (3): 298-306.
268. Xu C,Shen G,Yuan X, et al.ERK and JNK signaling pathways are involved in the regulation of activator protein 1 and cell death elicited by three isothiocyanates in human prostate cancer PC-3 cells.Carcinogenesis. 2006;27 (3): 437-45.
269. Jiang C,Wang Z,Ganther H,Lu J.Distinct effects of methylseleninic acid versus selenite on apoptosis, cell cycle, and protein kinase pathways in DU145 human prostate cancer cells.Mol Cancer Ther. 2002;1 (12): 1059-66.
270. Maeda H,Hori S,Nishitoh H, et al.Tumor growth inhibition by arsenic trioxide (As2O3) in the orthotopic metastasis model of androgen-independent prostate cancer.Cancer Res. 2001;61 (14): 5432-40.
271. Xiao D,Singh SV.Phenethyl isothiocyanate-induced apoptosis in p53-deficient PC-3 human prostate cancer cell line is mediated by extracellular signal-regulated kinases.Cancer Res. 2002;62 (13): 3615-9.
272. Murillo H,Schmidt LJ,Tindall DJ.Tyrphostin AG825 triggers p38 mitogen-activated protein kinase-dependent apoptosis in androgen-independent prostate cancer cells C4 and C4-2.Cancer Res. 2001;61 (20): 7408-12.
273. Cho SD,Ahn NS,Jung JW, et al.Critical role of the c-JunNH2-terminal kinase and p38 mitogen-activated protein kinase pathways on sodium butyrate-induced apoptosis in DU145 human prostate cancer cells.Eur J Cancer Prev. 2006;15 (1): 57-63.
274. Ricote M,Garcia-Tunon I,Fraile B, et al.P38 MAPK protects against TNF-alpha-provoked apoptosis in LNCaP prostatic cancer cells.Apoptosis. 2006;11 (11): 1969-75.